The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the 2020-2027 forecast period. The market reached $102bn in 2016,
This product candidate is currently under preclinical development. Several in vivo proof-of-concepts in rodents and non-rodents species have been successfully obtained.
Upon intravenous administration SOLUDOTS are stable and small enough to circulate in the blood stream for sufficient periods of time allowing them to extravasate from the tumor-associated blood vessels through their fenestrations therefore reaching solid tumors. Such phenomenon is known as passive targeting or enhanced permetion and retention effect.